大动脉炎发病机制及诊疗研究进展

doi:10.16138/j.1673-6087.2022.03.018

摘要/Abstract

关键词: 大动脉炎, 发病机制, 治疗原则, 免疫

中图分类号:

R593.27

孔秀芳, 姜林娣. 大动脉炎发病机制及诊疗研究进展[J]. 内科理论与实践, 2022, 17(03): 262-266.

参考文献 55

[1]	Watts RA, Hatemi G, Burns JC, et al. Global epidemiology of vasculitis[J]. Nat Rev Rheumatol, 2021, 18(1): 22-34. doi: 10.1038/s41584-021-00718-8 URL
[2]	Sun Y, Yin MM, Ma LL, et al. Epidemiology of Takayasu arteritis in Shanghai: a hospital-based study and systematic review[J]. Int J Rheum Dis, 2021, 24(10): 1247-1256. doi: 10.1111/1756-185X.14183 URL
[3]	Hirsch MS, Aikat BK, Basu AK. Takayasu’s arteritis[J]. Bull Johns Hopkins Hosp, 1964, 115: 29-64.
[4]	Naito S, Arakawa K, Saito S, et al. Takayasu’s disease: association with HLA-B5[J]. Tissue Antigens, 1978, 12(2): 143-145. pmid: 30183
[5]	Terao C, Yoshifuji H, Matsumura T, et al. Genetic determinants and an epistasis of LILRA3 and HLA-B*52 in Takayasu arteritis[J]. Proc Natl Acad Sci U S A, 2018, 115(51): 13045-13050. doi: 10.1073/pnas.1808850115 URL
[6]	Yajima M, Numano F, Park YB, et al. Comparative studies of patients with Takayasu arteritis in Japan, Korea and India-comparison of clinical manifestations, angiography and HLA-B antigen[J]. Jpn Circ J, 1994, 58(1): 9-14. pmid: 7908064
[7]	Vargas-Alarcón G, Hernández-Pacheco G, Soto ME, et al. Comparative study of the residues 63 and 67 on the HLA-B molecule in patients with Takayasu’s arteritis[J]. Immunol Lett, 2005, 96(2): 225-229. pmid: 15585327
[8]	Yoshida M, Kimura A, Katsuragi K, et al. DNA typing of HLA-B gene in Takayasu’s arteritis[J]. Tissue Antigens, 1993, 42(2): 87-90. pmid: 7903491
[9]	Kitamura H, Kobayashi Y, Kimura A, et al. Association of clinical manifestations with HLA-B alleles in Takayasu arteritis[J]. Int J Cardiol, 1998, 66 Suppl 1: S121-S126. doi: 10.1016/s0167-5273(98)00159-4 pmid: 9951811
[10]	Saruhan-Direskeneli G, Hughes T, Aksu K, et al. Identification of multiple genetic susceptibility loci in Takayasu arteritis[J]. Am J Hum Genet, 2013, 93(2): 298-305. doi: 10.1016/j.ajhg.2013.05.026 pmid: 23830517
[11]	Terao C, Yoshifuji H, Kimura A, et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population[J]. Am J Hum Genet, 2013, 93(2): 289-297. doi: 10.1016/j.ajhg.2013.05.024 URL
[12]	Terao C, Yoshifuji H, Kimura A, et al. Two susceptibility loci to Takayasu arteritis reveal a synergistic role of the IL12B and HLA-B regions in a Japanese population[J]. Am J Hum Genet, 2013, 93(2): 289-297. doi: 10.1016/j.ajhg.2013.05.024 URL
[13]	Renauer PA, Saruhan-Direskeneli G, Coit P, et al. Identification of susceptibility loci in IL6, RPS9/LILRB3, and an intergenic locus on chromosome 21q22 in Takayasu arteritis in a genome-wide association study[J]. Arthritis Rheumatol, 2015, 67(5): 1361-1368. doi: 10.1002/art.39035 URL
[14]	Kong X, Sun Y, Ma L, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis[J]. Clin Exp Rheumatol, 2016, 34(3 Suppl 97): S21-S27.
[15]	Kong X, Sawalha AH. Takayasu arteritis risk locus in IL6 represses the anti-inflammatory gene GPNMB through chromatin looping and recruiting MEF2-HDAC complex[J]. Ann Rheum Dis, 2019, 78(10): 1388-1397. doi: 10.1136/annrheumdis-2019-215567 URL
[16]	Ripoll VM, Irvine KM, Ravasi T, et al. Gpnmb is induced in macrophages by IFN-gamma and lipopolysaccharide and acts as a feedback regulator of proinflammatory responses[J]. J Immunol, 2007, 178(10): 6557-6566. doi: 10.4049/jimmunol.178.10.6557 pmid: 17475886
[17]	Ortiz-Fernández L, Saruhan-Direskeneli G, Alibaz-Oner F, et al. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study[J]. Am J Hum Genet, 2021, 108(1): 84-99. doi: 10.1016/j.ajhg.2020.11.014 pmid: 33308445
[18]	Berti A, Dejaco C. Update on the epidemiology, risk factors, and outcomes of systemic vasculitides[J]. Best Pract Res Clin Rheumatol, 2018, 32(2): 271-294. doi: 10.1016/j.berh.2018.09.001 URL
[19]	Pedreira ALS, Santiago MB. Association between Takayasu arteritis and latent or active mycobacterium tuberculosis infection: a systematic review[J]. Clin Rheumatol, 2020, 39(4): 1019-1026. doi: 10.1007/s10067-019-04818-5 pmid: 31729680
[20]	Zhang Y, Fan P, Luo F, et al. Tuberculosis in Takayasu arteritis: a retrospective study in 1105 Chinese patients[J]. J Geriatr Cardiol, 2019, 16(8): 648-655. doi: 10.11909/j.issn.1671-5411.2019.08.003 pmid: 31555333
[21]	Soto ME, Del Carmen ávila-Casado M, Huesca-Gómez C, et al. Detection of IS6110 and HupB gene sequences of Mycobacterium tuberculosis and bovis in the aortic tissue of patients with Takayasu’s arteritis[J]. BMC Infect Dis, 2012, 12: 194. doi: 10.1186/1471-2334-12-194 URL
[22]	Kumar Chauhan S, Kumar Tripathy N, Sinha N, et al. Cellular and humoral immune responses to mycobacterial heat shock protein-65 and its human homologue in Takayasu’s arteritis[J]. Clin Exp Immunol, 2004, 138(3): 547-553. pmid: 15544635
[23]	Li T, Gao N, Cui W, et al. Natural killer cells and their function in Takayasu’s arteritis[J]. Clin Exp Rheumatol, 2020, 38 Suppl 124(2):84-90.
[24]	Seko Y. Takayasu arteritis: insights into immunopathology[J]. Jpn Heart J, 2000, 41(1): 15-26. pmid: 10807525
[25]	Graver JC, Boots AMH, Haacke EA, et al. Massive B-cell infiltration and organization into artery tertiary lymphoid organs in the aorta of large vessel giant cell arteritis[J]. Front Immunol, 2019, 10: 83. doi: 10.3389/fimmu.2019.00083 URL
[26]	Saadoun D, Garrido M, Comarmond C, et al. Th1 and Th17 cytokines drive inflammation in Takayasu arteritis.[J]. Arthritis Rheumatol, 2015, 67(5): 1353-1360. doi: 10.1002/art.39037 URL
[27]	Mutoh T, Shirai T, Ishii T, et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis[J]. Nat Commun, 2020, 11(1): 1253. doi: 10.1038/s41467-020-15088-0 URL
[28]	Alibaz-Oner F, Yentür SP, Saruhan-Direskeneli G, et al. Serum cytokine profiles in Takayasu’s arteritis: search for biomarkers[J]. Clin Exp Rheumatol, 2015, 33(2 Suppl 89): 32-35.
[29]	Savioli B, Abdulahad WH, Brouwer E, et al. Are cytokines and chemokines suitable biomarkers for Takayasu arteritis?[J]. Autoimmun Rev, 2017, 16(10): 1071-1078. doi: S1568-9972(17)30206-9 pmid: 28778711
[30]	Park MC, Lee SW, Park YB, et al. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis[J]. Rheumatology (Oxford), 2006, 45(5): 545-548. doi: 10.1093/rheumatology/kei266 URL
[31]	Li J, Wang Y, Wang Y, et al. Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasu’s arteritis patients[J]. Arthritis Res Ther, 2020, 22(1): 285. doi: 10.1186/s13075-020-02365-y URL
[32]	Dhawan V, Mahajan N, Jain S. Role of C-C chemokines in Takayasu’s arteritis disease[J]. Int J Cardiol, 2006, 112(1): 105-111. pmid: 16647147
[33]	Wu G, Mahajan N, Dhawan V. Acknowledged signatures of matrix metalloproteinases in Takayasu’s arteritis[J]. Biomed Res Int, 2014, 2014: 827105.
[34]	Mahajan N, Dhawan V, Malik S, et al. Implication of oxidative stress and its correlation with activity of matrix metalloproteinases in patients with Takayasu’s arteritis disease[J]. Int J Cardiol, 2010, 145(2): 286-288. doi: S0167-5273(09)01518-6 pmid: 19913312
[35]	Matsuyama A, Sakai N, Ishigami M, et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis[J]. Circulation, 2003, 108(12): 1469-1473. doi: 10.1161/01.CIR.0000090689.69973.B1 pmid: 12952836
[36]	Régnier P, Le Joncour A, Maciejewski-Duval A, et al. Targeting JAK/STAT pathway in Takayasu’s arteritis[J]. Ann Rheum Dis, 2020, 79(7): 951-959. doi: 10.1136/annrheumdis-2019-216900 pmid: 32213496
[37]	Watanabe R, Berry GJ, Liang DH, et al. Cellular signaling pathways in medium and large vessel vasculitis[J]. Front Immunol, 2020, 11: 587089. doi: 10.3389/fimmu.2020.587089 URL
[38]	Maciejewski-Duval A, Comarmond C, Leroyer A, et al. mTOR pathway activation in large vessel vasculitis[J]. J Autoimmun, 2018, 94: 99-109. doi: S0896-8411(18)30228-2 pmid: 30061014
[39]	Bursi R, Cafaro G, Perricone C, et al. Contribution of Janus-kinase/signal transduction activator of transcription pathway in the pathogenesis of vasculitis[J]. Front Pharmacol, 2021, 12: 635663. doi: 10.3389/fphar.2021.635663 URL
[40]	Zhang H, Watanabe R, Berry GJ, et al. Inhibition of JAK-STAT signaling suppresses pathogenic immune responses in medium and large vessel vasculitis[J]. Circulation, 2018, 137(18): 1934-1948. doi: 10.1161/CIRCULATIONAHA.117.030423 pmid: 29254929
[41]	Régnier P, Le Joncour A, Maciejewski-Duval A, et al. Targeting JAK/STAT pathway in Takayasu’s arteritis[J]. Ann Rheum Dis, 2020, 79(7): 951-959. doi: 10.1136/annrheumdis-2019-216900 pmid: 32213496
[42]	Hadjadj J, Canaud G, Mirault T, et al. mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G[J]. Rheumatology (Oxford), 2018, 57(6): 1011-1020. doi: 10.1093/rheumatology/key017 pmid: 29506143
[43]	Ishihara T, Haraguchi G, Kamiishi T, et al. Sensitive assessment of activity of Takayasu’s arteritis by pentraxin 3, a new biomarker[J]. J Am Coll Cardiol, 2011, 57(16): 1712-1713. doi: 10.1016/j.jacc.2010.10.058 pmid: 21492771
[44]	Matsuyama A, Sakai N, Ishigami M, et al. Matrix metalloproteinases as novel disease markers in Takayasu arteritis[J]. Circulation, 2003, 108(12): 1469-1473. doi: 10.1161/01.CIR.0000090689.69973.B1 pmid: 12952836
[45]	Park MC, Lee SW, Park YB, et al. Serum cytokine profiles and their correlations with disease activity in Takayasu’s arteritis[J]. Rheumatology (Oxford), 2006, 45(5): 545-548. doi: 10.1093/rheumatology/kei266 URL
[46]	Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and takayasu arteritis[J]. Arthritis Care Res (Hoboken), 2021, 73(8): 1349-1365.
[47]	Kenar G, Karaman S, Çetin P, et al. Imaging is the major determinant in the assessment of disease activity in Takayasu’s arteritis[J]. Clin Exp Rheumatol, 2020, 38 Suppl 124(2):55-60.
[48]	Ma LY, Li CL, Ma LL, et al. Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis[J]. Arthritis Res Ther, 2019, 21(1): 24. doi: 10.1186/s13075-019-1813-2 URL
[49]	Sun Y, Huang Q, Jiang L. Radiology and biomarkers in assessing disease activity in Takayasu arteritis[J]. Int J Rheum Dis, 2019, 22 Suppl 1: 53-59.
[50]	Padoan R, Crimì F, Felicetti M, et al. Fully integrated 18F-FDG PET/MR in large vessel vasculitis[J]. Q J Nucl Med Mol Imaging, 2019.[Epub ahead of print].
[51]	Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasu’s arteriopathy[J]. J Am Coll Cardiol, 1988, 12(4): 964-972. pmid: 2901440
[52]	Sharma BK, Jain S, Suri S, et al. Diagnostic criteria for Takayasu arteritis[J]. Int J Cardiol, 1996, 54 Suppl: S141-S147. doi: 10.1016/s0167-5273(96)88783-3 pmid: 9119516
[53]	Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis[J]. Arthritis Rheum, 1990, 33(8): 1129-1134. doi: 10.1002/art.1780330811 URL
[54]	Peter Grayson, Raashid Luqmani. ACR convergence 2021. oral presentation at 9th Nov.
[55]	Comarmond C, Biard L, Lambert M, et al. Long-term outcomes and prognostic factors of complications in Takayasu arteritis[J]. Circulation, 2017, 136(12): 1114-1122. doi: 10.1161/CIRCULATIONAHA.116.027094 pmid: 28701469

大动脉炎发病机制及诊疗研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 55

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵晨薇　马刚　林晓曦. 葡萄酒色斑增厚机制的研究进展[J]. 组织工程与重建外科杂志, 2022, 18(1): 83-.
[2]	赵含丹, 许利军. 人类免疫缺陷病毒相关隐球菌脑膜炎的诊治现状和挑战[J]. 诊断学理论与实践, 2022, 21(04): 419-424.
[3]	陈志敏, 何浩岚. 艾滋病合并马尔尼菲篮状菌病的诊治现状[J]. 诊断学理论与实践, 2022, 21(04): 425-430.
[4]	陈志敏, 刘波, 何浩岚, 何耀祖, 冯理智, 刘新华, 张坚生, 蔡卫平, 李凌华. 133例艾滋病合并马尔尼菲篮状菌病死亡病例分析[J]. 诊断学理论与实践, 2022, 21(04): 444-449.
[5]	胡静静, 吕海伟, 荀静娜, 沈银忠, 刘莉, 卢洪洲. 2012年至2021年上海市艾滋病合并分枝杆菌感染患者的菌种分布特征[J]. 诊断学理论与实践, 2022, 21(04): 450-455.
[6]	高晶晶, 高艳虹. 早发2型糖尿病流行病学、临床特征及病因机制的研究进展[J]. 内科理论与实践, 2022, 17(04): 344-348.
[7]	陈晓娟, 张雯, 蔡瑜. 经导管脾动脉栓塞术治疗胰源性门静脉高压致消化道出血(附1例报告)[J]. 外科理论与实践, 2022, 27(04): 359-362.
[8]	陈宏, 沈银忠. 人类免疫缺陷病毒感染/艾滋病合并结核病的诊治进展[J]. 诊断学理论与实践, 2022, 21(04): 530-534.
[9]	汤建平, 龚邦东. 干燥综合征的诊治现状、挑战和思考[J]. 诊断学理论与实践, 2022, 21(03): 291-298.
[10]	李佳, 吕良敬. 靶向治疗时代议自身免疫病的感染挑战[J]. 诊断学理论与实践, 2022, 21(03): 299-303.
[11]	牟兴, 叶倩仪, 卢红娟, 徐沪济, 吴歆. 季节变化对风湿病发病机制及病情活动的影响[J]. 诊断学理论与实践, 2022, 21(03): 304-311.
[12]	刘萍, 肖园, 王歆琼, 陆亭伟, 赵雪松, 杨媛艳. Wiskott-Aldrich综合征合并克罗恩病一例并文献复习[J]. 诊断学理论与实践, 2022, 21(03): 349-354.
[13]	赵东宝. 风湿病继发骨质疏松症研究进展[J]. 内科理论与实践, 2022, 17(03): 181-185.
[14]	王宏智, 袁昳玮. 类风湿关节炎的慢病管理[J]. 内科理论与实践, 2022, 17(03): 202-207.
[15]	张春丽, 徐静, 潘晓霞, 胡晓帆, 李娅. IgG4相关肾病临床及病理特征分析[J]. 内科理论与实践, 2022, 17(03): 214-219.